Web Calculator Estimates Survival of Bowel Cancer Patients
By LabMedica International staff writers Posted on 28 Jun 2017 |
For many cancer patients, their diagnosis is soon followed by thoughts of trying to estimate how much time they have left and whether certain treatments could prolong their life. The new online prognostic tool could help manage expectations and make more informed decisions about treatment options.
The calculator was developed by researchers at the University of Nottingham (UN; Nottingham, UK) and medical software company ClinRisk (UK) using the QResearch database, which gathers patient data from approximately 1500 general practices across England through the clinical IT computer systems of EMIS Health. QResearch is a large consolidated database of anonymous health records, developed by a not-for-profit partnership between the UN and EMIS.
“We are grateful for the continued commitment of practices using our systems and their patients who are helping to improving healthcare through data analytics,” said Shaun O’Hanlon, medical director at EMIS Health, “While having the best information is always important, it is how it is delivered and used that is key.”
Accuracy testing showed that the calculator can predict absolute survival rates. It also allows patients to update their mortality risk based on how long they have survived following a diagnosis of cancer.
“Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions,” said Prof. Hippisley-Cox, “This new calculator, which doctors and patients can access, will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it’s an individual choice.”
Current methods of predicting survival are based on simple averages based on age or the grade and stage of the cancer in the wider population. To deliver a far more personalized prognosis, the new tool takes into account additional risk factors, including the patient’s smoking history, body mass index, family history, other illnesses and treatments (e.g. aspirin or statins), as well as other information (e.g. whether they have had surgery or treatments such as chemotherapy for the cancer).
The team used information from more than 44,000 patients from 947 practices to develop separate equations for men and women aged between 15-99 years when diagnosed with bowel cancer. They then tested the equations by using them retrospectively to predict the outcome at 1, 5, and 10 years after diagnosis for 15,214 bowel cancer patients from 305 different GP practices, and for 437,821 colorectal cancer patients from the national cancer registry.
The results indicated that they had devised strong models for prediction of cancer survival outcomes. They were also able to provide conditional survival estimates that showed how mortality risks change over time, particularly important among patients where the initial prognosis was poor due to late-stage disease.
For example, a 38-year-old woman with stage 4 advanced bowel cancer might the calculator and see that her chance of surviving for 5 years without any treatment would be predicted to be only 6%; with surgery it would increase to 23%, and with both treatments it would be 45%. This compares with the published chance of 5-year survival of 66% based solely on her age, or the 8% chance based solely on her cancer stage. If she has both treatments and survives for 1 year following diagnosis, her predicted 5-year conditional survival would increase to 57%.
The study, by Hippisley-Cox J and Coupland C, was published June 15, 2017, in the British Medical Journal (BMJ).
Related Links:
University of Nottingham
ClinRisk
The calculator was developed by researchers at the University of Nottingham (UN; Nottingham, UK) and medical software company ClinRisk (UK) using the QResearch database, which gathers patient data from approximately 1500 general practices across England through the clinical IT computer systems of EMIS Health. QResearch is a large consolidated database of anonymous health records, developed by a not-for-profit partnership between the UN and EMIS.
“We are grateful for the continued commitment of practices using our systems and their patients who are helping to improving healthcare through data analytics,” said Shaun O’Hanlon, medical director at EMIS Health, “While having the best information is always important, it is how it is delivered and used that is key.”
Accuracy testing showed that the calculator can predict absolute survival rates. It also allows patients to update their mortality risk based on how long they have survived following a diagnosis of cancer.
“Current methods of estimating survival tend to be unreliable and sometimes patients can be given a fairly misleading and unnecessarily gloomy prognosis based only on the grade and stage of their cancer, only to find that in reality they live much longer than these crude predictions,” said Prof. Hippisley-Cox, “This new calculator, which doctors and patients can access, will offer a far more realistic estimate. We understand that not everyone will want to do this, of course, but some patients are very keen on this approach so it’s an individual choice.”
Current methods of predicting survival are based on simple averages based on age or the grade and stage of the cancer in the wider population. To deliver a far more personalized prognosis, the new tool takes into account additional risk factors, including the patient’s smoking history, body mass index, family history, other illnesses and treatments (e.g. aspirin or statins), as well as other information (e.g. whether they have had surgery or treatments such as chemotherapy for the cancer).
The team used information from more than 44,000 patients from 947 practices to develop separate equations for men and women aged between 15-99 years when diagnosed with bowel cancer. They then tested the equations by using them retrospectively to predict the outcome at 1, 5, and 10 years after diagnosis for 15,214 bowel cancer patients from 305 different GP practices, and for 437,821 colorectal cancer patients from the national cancer registry.
The results indicated that they had devised strong models for prediction of cancer survival outcomes. They were also able to provide conditional survival estimates that showed how mortality risks change over time, particularly important among patients where the initial prognosis was poor due to late-stage disease.
For example, a 38-year-old woman with stage 4 advanced bowel cancer might the calculator and see that her chance of surviving for 5 years without any treatment would be predicted to be only 6%; with surgery it would increase to 23%, and with both treatments it would be 45%. This compares with the published chance of 5-year survival of 66% based solely on her age, or the 8% chance based solely on her cancer stage. If she has both treatments and survives for 1 year following diagnosis, her predicted 5-year conditional survival would increase to 57%.
The study, by Hippisley-Cox J and Coupland C, was published June 15, 2017, in the British Medical Journal (BMJ).
Related Links:
University of Nottingham
ClinRisk
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more